JP EN
HOME/Announcement Regarding the Acquisition of Vivixy as a Subsidiary

2026.01.26Announcement Regarding the Acquisition of Vivixy as a Subsidiary

Medical Intelligence Holdings Co., Ltd. (Headquarters: Osaka City, Osaka Prefecture; hereinafter "MIHD") hereby announces that it has acquired 51% of the issued and outstanding shares of Vivixy Co., Ltd. (Headquarters: Chiyoda-ku, Tokyo; hereinafter "Vivixy"), making it a subsidiary of MIHD (hereinafter "this Transaction").

Through this Transaction, MIHD aims to further strengthen its business foundation in the medical field.

Purpose of the Subsidiarizatio

MIHD holds subsidiaries including Medical Review Co., Ltd., Interscience Co., Ltd., Medical Professional Relations Co., Ltd., and Hearts Co., Ltd. Through these group companies, it operates medical publishing and advertising agency services specializing in prescription pharmaceuticals. Over many years, it has built a robust network with pharmaceutical companies and established a solid network and reach to physicians through medical education and promotional activities.

Meanwhile, Vivixy, as a systems company with engineers proficient in AI and web technologies, has strengthened its ability to solve problems aligned with the realities of the medical field and its development capabilities to rapidly implement cutting-edge AI technologies in real-world settings.

This Transaction aims to combine MIHD’s robust business foundation with Vivixy’s AI development capabilities. We will drive the creation of new AI-based businesses and promote AI utilization across the entire MIHD Group, aiming for digital transformation (DX) across healthcare settings and the creation of new value.

Future Initiatives

Leveraging MIHD’s business platform and Vivixy’s technological capabilities, we will consider and promote the following initiatives:

  • Joint development of new AI solutions for healthcare professionals
  • Phased implementation and provision of AI functions for existing services
  • Expansion of marketing channels for pharmaceutical companies and medical device manufacturers
  • Promotion of AI utilization across the MIHD Group